Top

Published in:

01-03-2011 | Movement Disorders - Review Article

Iron chelation and neuroprotection in neurodegenerative diseases

Authors: Xuping Li, Joseph Jankovic, Weidong Le

Published in: Journal of Neural Transmission | Issue 3/2011

Abstract

Iron is an essential element for multiple functions of the brain. Maintenance of iron homeostasis involves regulation of iron influx, iron efflux and iron storage. Mismanagement of brain iron has been implicated in neuronal injury and death in several neurodegenerative diseases, such as Parkinson’s disease (PD), Alzheimer’s disease (PD) and Amyotrophic lateral sclerosis (ALS). Multiple iron chelators have been shown neuroprotective and neurorestorative in these diseases, suggesting that iron chelation might be a promising therapeutics. In this paper, we briefly review the new findings of biological function of several molecules that regulate iron homeostasis in the brain, the possible role of iron mismanagement in the pathogenesis of PD, AD and ALS, and then discuss the putative mechanisms for current available iron chelators as potential therapeutics for neurodegenerative diseases.

Amit T, Avramovich-Tirosh Y, Youdim MB et al (2008) Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 22:1296–1305PubMedCrossRef

Arosio P, Ingrassia R, Cavadini P (2009) Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790:589–599PubMed

Avramovich-Tirosh Y, Reznichenko L, Mit T et al (2007) Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelatingantioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4:403–411PubMedCrossRef

Avramovich-Tirosh Y, Bar-Am O, Amit T et al (2009) Up-regulation of Hypoxia-Inducible Factor (HIF)-1alpha and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30. Curr Alzheimer Res [epub ahead of print]

Bartzokis G, Lu PH, Tishler TA et al (2010) Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J Alzheimers Dis 20:333–341PubMed

Benarroch EE (2009) Brain iron homeostasis and neurodegenerative disease. Neurology 72:1436–1440PubMedCrossRef

Burmester T, Hankeln T (2009) What is the function of neuroglobin? J Exp Biol 212:1423–1428PubMedCrossRef

Cantu D, Schaack J, Patel M (2009) Oxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures. PLoS One 4:e7095PubMedCrossRef

Castellani RJ, Moreira PI, Liu G et al (2007) Iron: the redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 32:1640–1645PubMedCrossRef

Cozzi A, Rovelli E, Frizzale G et al (2010) Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol Dis 37:77–85PubMedCrossRef

Crouch PJ, White AR, Bush AI (2007) The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer’s disease. FEBS J 274:3775–3783PubMedCrossRef

Dong XP, Cheng X, Mills E et al (2008) The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature 455:992–996PubMedCrossRef

Double KL, Halliday GM (2006) New face of neuromelanin. J Neural Transm Suppl 70:119–123PubMedCrossRef

Gal S, Zheng H, Fridkin M et al (2010) Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 17:15–27PubMedCrossRef

Jeong SY, Rathore KI, Schulz K et al (2009) Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci 29:610–619PubMedCrossRef

Jiang D, Li X, Williams R et al (2009) Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer’s disease. Biochemistry 48:7939–7947PubMedCrossRef

Jin K, Mao Y, Mao X et al (2010) Neuroglobin expression in ischemic stroke. Stroke 41:557–559PubMedCrossRef

Johansson AC, Appelqvist H, Nilsson C et al (2010) Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 15:527–540PubMedCrossRef

Kaur D, Yantiri F, Rajagopalan S et al (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37:899–909PubMedCrossRef

Kupershmidt L, Weinreb O, Amit T et al (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23:3766–3779PubMedCrossRef

Lee DW, Rajagopalan S, Siddiq A et al (2009) Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 284:29065–29076PubMedCrossRef

Lim GP, Chu T, Yang F et al (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:8370–8377PubMed

Lovell MA, Xiong S, Xie C et al (2004) Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis 6:659–671PubMed

Mastroberardino PG, Hoffman EK, Horowitz MP et al (2009) A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson’s disease. Neurobiol Dis 34:417–431PubMedCrossRef

McCormack AL, Atienza JG, Johnston LC et al (2005) Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem 93:1030–1037PubMedCrossRef

Moreira PI, Sayre LM, Zhu X et al (2010) Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. Methods Mol Biol 610:419–434PubMedCrossRef

Ong WY, Farooqui AA (2005) Iron, neuroinflammation, and Alzheimer’s disease. J Alzheimers Dis 8:183–200PubMed

Ortega R, Cloetens P, Devès G et al (2007) Iron storage within dopamine neurovesicles revealed by chemical nano-imaging. PLoS One 2:e925PubMedCrossRef

Perez CA, Tong Y, Guo M (2008) Iron chelators as potential therapeutic agents for Parkinson’s disease. Curr Bioact Compd 4:150–158PubMedCrossRef

Quintana C, Bellefqih S, Laval JY et al (2006) Study of the localization of iron, ferritin, and hemosiderin in Alzheimer’s disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 153:42–54PubMedCrossRef

Reznichenko L, Kalfon L, Amit T et al (2010) low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in mptp-induced parkinsonism. Neurodegener Dis [epub ahead of print]

Rhodes SL, Ritz B (2008) Genetics of iron regulation and the possible role of iron in Parkinson’s disease. Neurobiol Dis 32:183–195PubMedCrossRef

Salazar J, Mena N, Hunot S et al (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson’s disease. Proc Natl Acad Sci USA 105:18578–18583PubMedCrossRef

Snyder AM, Connor JR (2009) Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 1790:606–614PubMed

Song N, Wang J, Jiang H et al (2010) Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson’s disease. Free Radic Biol Med 48:332–341PubMedCrossRef

Whitnall M, Richardson DR (2006) Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 13:186–197PubMedCrossRef

Xu Z, Chen S, Li X et al (2006) Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral schlerosis. Neurochem Res 31:1263–1269PubMedCrossRef

Youdim MB, Fridkin M, Zheng H (2005) Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 126:317–326PubMedCrossRef

Youdim MB, Grünblatt E, Mandel S (2007) The copper chelator, D-penicillamine does not attenuate MPTP induced dopamine depletion in mice. J Neural Transm 114:205–209PubMedCrossRef

Zbarsky V, Datla KP, Parkar S et al (2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radic Res 39:1119–1125PubMedCrossRef

Zhang X, Xie W, Qu S et al (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophys Res Commun 333:544–549PubMedCrossRef

Zheng W, Xin N, Chi ZH et al (2009) Divalent metal transporter 1 is involved in amyloid precursor protein processing and Abeta generation. FASEB J 23:4207–4217PubMedCrossRef

Zhu W, Xie W, Pan T et al (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21:3835–3844PubMedCrossRef

Zhu W, Li X, Xie W et al (2010) Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis 37:307–313PubMedCrossRef

Title: Iron chelation and neuroprotection in neurodegenerative diseases
Authors: Xuping Li
Joseph Jankovic
Weidong Le
Publication date: 01-03-2011
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 3/2011
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-010-0518-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Iron chelation and neuroprotection in neurodegenerative diseases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+)

Iron-dependent functions of mitochondria—relation to neurodegeneration

Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells

Iron and the immune system

The link between iron, metabolic syndrome, and Alzheimer’s disease

Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain